For women with ER-positive breast cancer, the decision regarding foregoing estrogen replacement therapy post-menopause differs from prostate cancer biology.

“is there an analogy here in breast cancer where obviously if a woman has ER positive breast cancer and it's metastatic well you're going to have you know unfortunately you're going to be dealing with anti-estrogen therapy indefinitely um but if you're talking about a stage one cancer or a stage two cancer or even a stage three where you have a Neo adant treatment you have a pathologic CR as far as you're concerned there's no evidence of disease are those women still uh told to forego estrogen replacement therapy in in postmenopause and if so why the difference from the biology of prostate cancer”